bdp 12 has been researched along with clozapine in 5 studies
| Studies (bdp 12) | Trials (bdp 12) | Recent Studies (post-2010) (bdp 12) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
|---|---|---|---|---|---|
| 62 | 7 | 14 | 9,691 | 747 | 3,148 |
| Protein | Taxonomy | bdp 12 (IC50) | clozapine (IC50) |
|---|---|---|---|
| Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
| D | Rattus norvegicus (Norway rat) | 1.066 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
| Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
| Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
| Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
| Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
| D | Bos taurus (cattle) | 4.09 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berman, I; Goff, DC; Herz, L; Johnson, SA; Leahy, L; Leon, AC; Lynch, G; Posever, T | 1 |
| Tiihonen, J; Tuominen, HJ; Wahlbeck, K | 1 |
| Didriksen, M; Kreilgaard, M; Olsen, CK | 1 |
| Freudenreich, O; Goff, DC; Green, MF; Johnson, SA; Lamberti, JS; Leon, AC; Manschreck, T; Miller, AL; Patel, J | 1 |
| Begemann, MJ; Leucht, S; Sommer, IE; Temmerman, A | 1 |
2 review(s) available for bdp 12 and clozapine
| Article | Year |
|---|---|
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.
Topics: Clozapine; Cycloserine; Dioxoles; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Agents; Glycine; Humans; Hydro-Lyases; Molindone; Piperidines; Schizophrenia | 2005 |
Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Citalopram; Clozapine; Dioxoles; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fructose; Humans; Lamotrigine; Piperidines; Psychiatric Status Rating Scales; Psychotropic Drugs; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sulpiride; Topiramate; Treatment Outcome; Triazines | 2012 |
2 trial(s) available for bdp 12 and clozapine
| Article | Year |
|---|---|
A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Clozapine; Cognition; Dioxoles; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Memory; Middle Aged; Pilot Projects; Piperidines; Psychological Tests; Schizophrenia | 2001 |
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dioxoles; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Pilot Projects; Piperidines; Psychiatric Status Rating Scales; Psychomotor Performance; Risperidone; Sample Size; Schizophrenia; Schizophrenic Psychology | 2008 |
1 other study(ies) available for bdp 12 and clozapine
| Article | Year |
|---|---|
Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; Clozapine; Conditioning, Psychological; Dioxoles; Drug Synergism; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperidines; Pyrimidines; Rats; Rats, Wistar; Receptors, AMPA; Risperidone; Serine; Stereoisomerism | 2006 |